ALNY Alnylam Pharmaceuticals Inc.
NewsSee all news
-
Alnylam to Webcast Presentations at Upcoming December Investor Conferences
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Evercore ISI 2nd Annual HealthCONx
-
Alnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day
− Expects to Exceed Alnylam 2020 Goals with Four Marketed Products, 14 Organic Clinical Stage Programs, Including 6 in Late-Stage Development, Across 4 Strategic Therapeutic Areas (STArs), by End of 2020 – – Initiates
-
Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI™ (givosiran)
− Framework Ties Payment for GIVLAARI to its Delivery of Patient Outcomes in the Real-World Setting - − Includes New Approach Designed for Ultra-Rare Diseases that Gives Participating Payers Greater Financial
-
Alnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA)
− GIVLAARI Approved for the Treatment of Adults with Acute Hepatic Porphyria (AHP) Based on ENVISION Phase 3 Study Results Showing Significant Reduction in the Rate of Porphyria Attacks in Patients with AHP – − FDA
-
Alnylam Announces Second Annual Advocacy for Impact Grants Program
− Program Aims to Inspire Creative Patient Advocacy Solutions to Unique Challenges in Rare Disease Communities − − Funding Will Support Unmet Needs in the ATTR Amyloidosis, Acute Hepatic Porphyria and Primary
Drug Information
Drug catalyst information is displayed when you hover over / tap on the stage bar graph.
Latest News
-
Alnylam to Webcast Presentations at Upcoming December Investor Conferences
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Evercore ISI 2nd Annual HealthCONx
-
Alnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day
− Expects to Exceed Alnylam 2020 Goals with Four Marketed Products, 14 Organic Clinical Stage Programs, Including 6 in Late-Stage Development, Across 4 Strategic Therapeutic Areas (STArs), by End of 2020 – – Initiates
-
Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI™ (givosiran)
− Framework Ties Payment for GIVLAARI to its Delivery of Patient Outcomes in the Real-World Setting - − Includes New Approach Designed for Ultra-Rare Diseases that Gives Participating Payers Greater Financial
-
Alnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA)
− GIVLAARI Approved for the Treatment of Adults with Acute Hepatic Porphyria (AHP) Based on ENVISION Phase 3 Study Results Showing Significant Reduction in the Rate of Porphyria Attacks in Patients with AHP – − FDA
-
Alnylam Announces Second Annual Advocacy for Impact Grants Program
− Program Aims to Inspire Creative Patient Advocacy Solutions to Unique Challenges in Rare Disease Communities − − Funding Will Support Unmet Needs in the ATTR Amyloidosis, Acute Hepatic Porphyria and Primary
-
Alnylam to Webcast Presentation at Stifel 2019 Healthcare Conference
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019
-
Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
− Initial Results From ILLUMINATE-C Expected in Late 2020 – − In Phase 2 OLE, Lumasiran Treatment Resulted in 76 percent Mean Maximal Reduction in Urinary Oxalate Relative to Phase 1/2 Baseline – Alnylam
-
Alnylam Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Period Activity
− Achieved Third Quarter 2019 ONPATTRO® Global Net Product Revenues of $46.1 Million, Including Initial Sales in Japan, with Over 600 Patients on Commercial Product Worldwide – − Initiated APOLLO-B Phase 3 Study of
-
Alnylam Named #1 Biopharma Employer by Science Magazine
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that Science magazine has named the company the world's number one employer in its annual survey of the biotech and
-
Alnylam's Distinguished Chemist Mano Manoharan Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Innovation Chemistry at Alnylam, has been awarded
-
Alnylam Announces Filing for Marketing Authorization of ONPATTRO® (patisiran) in Brazil for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
– Filing Marks the First RNAi Therapeutic to be Submitted for Potential Approval in Latin America – – Submission Made Under the Accelerated Regulatory Pathway for Rare Diseases – Alnylam Pharmaceuticals, Inc.
-
Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 2019 Cantor Global Healthcare Conference on Thursday, October 3,
-
Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
– APOLLO-B Will Enroll Patients with Both Hereditary and Wild-Type Amyloidosis – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated
-
Alnylam Presents New Evidence Demonstrating Significant Association of V122I, a Highly Prevalent, Pathogenic Transthyretin (TTR) Mutation, with Clinical Diagnosis of Polyneuropathy
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today presented new results from an analysis of the UK Biobank – a prospective cohort study with genetic, physical, and health data on
-
1,000 Alnylam Employees Across the Globe Volunteer at 5th Annual Community Service Day
− Alnylam Supports Nearly 40 Organizations in Greater Boston, Philadelphia, Europe and Brazil in "Helping Hands" Community Service Day – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics
-
Alnylam Presents New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias
− Porphyria Attack Reductions Observed in ENVISION Phase 3 Study Maintained with Ongoing Givosiran Dosing in Open-Label Extension (OLE) Study – − In ENVISION Phase 3 Study, Patients Receiving Givosiran Reported
-
Alnylam to Host Sixth Annual "RNAi Roundtable" Webcast Series
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it plans to kick off its 6th annual series of "RNAi Roundtable" webcasts over the coming weeks. The series will
-
Yumanity Therapeutics Appoints Patricia Allen to its Board of Directors
Ms. Allen Brings Over 25 Years of Financial Leadership Experience to the Company Yumanity Therapeutics, a company focused on discovering and developing transformative therapies to treat neurodegenerative diseases,
-
Alnylam Presents New Clinical Research Findings at the Second European Meeting of ATTR Amyloidosis for Doctors and Patients
− Neurofilament Light Chain (NfL) Identified as a Potential Biomarker of Nerve Damage and Polyneuropathy due to hATTR Amyloidosis; ONPATTRO® (patisiran) Treatment Found to Reduce NfL Levels Relative to Placebo in APOLLO
-
Alnylam Pharmaceuticals Provides Perspective on Positive Complete Results from ORION-11 Phase 3 Study of Inclisiran
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today provided perspective on the positive complete results from the ORION-11 Phase 3 study of inclisiran, an RNAi therapeutic in
-
Alnylam to Webcast Presentation at 17th Annual Morgan Stanley Global Healthcare Conference
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 17th Annual Morgan Stanley Global Healthcare Conference on